Objective: We introduce two cases of a 46 and 66-year-old patient, both diagnosed with pelvic neurofibroma (One located in a seminal vesicle, the other in the bladder). The first patient had been diagnosed with Neurofibromatosis type 1 while the other was diagnosed with a sporadic neurofibroma.
Methods: During a study for lower urinary tract symptoms referred, these patients were diagnosed seminal vesicle and bladder neurofibroma, respectively, using image and histological tests.
Results: The histopathological and inmunohistochemical characteristics of these benign tumors gave the definitive diagnosis.
Conclusions: Pelvic neurofibromas are a rare entity in this anatomical location. They can be associated with Neurofibromatosis type 1 or not. We get to their diagnosis by an anatomopathological study. Conservative management is the usual procedure, being mandatory a clinical follow-up that must be coupled with image tests.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aim: To assess the changes of intracranial pressure waveforms (ICPW) acquired noninvasively in a set of acute hydrocephalus patients prior to and posterior to interventions.
Material And Methods: Patients with clinical and radiological diagnoses of hydrocephalus were evaluated for alterations in ICPW by means of a system that detects cranial micro expansions just before and immediately after interventions. The system quantified the difference between ICPW peaks (P1 and P2), providing the P2/P1 ratio.
Erdheim Chester Disease with Calvarial Involvement: A rare case of Histiocytosis.
Turk Neurosurg
March 2024
SBÜ Gaziosmanpaşa Eğitim ve Araştırma Hastanesi.
Erdheim-Chester Disease is a rare systemic xanthogranulomatous infiltrating disease, characterized by lipid-laden histiocytes accumulating in various organs and almost always in bones. Etiology of the disease is still unknown. It may involve various organs and systems, such as musculoskeletal, cardiac, pulmonary, renal, gastrointestinal and central nervous system (CNS) as well as the skin.
View Article and Find Full Text PDFAim: Many combinations of inflammation-based markers have been reported their prognostic ability. The prognostic value of albumin-to-gama-glutamyltransferase ratio (AGR), an inflammation-related index, has been identified for several cancers. However, the predictive value of AGR for high-grade glioma patients remains unclear.
View Article and Find Full Text PDFAim: This study aims to assess the clinicopathological and prognostic significance of Tim-3, an immune checkpoint molecule, and Rel-B, an NF-κB subunit, in grade 4 diffuse glioma samples and their relationship with each other.
Material And Methods: The demographic, radiologic, prognostic, and treatment data of patients diagnosed with grade 4 diffuse glioma between 2016 and 2019 were reviewed and recorded. Tim-3 and Rel-B were applied to the paraffin-embedded tissues by immunohistochemistry method.
Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.
Diabetes Obes Metab
January 2025
Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
Aims: Evaluate glycated haemoglobin (HbA1c) and weight changes after 6 months of once-weekly (QW) injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in UK primary care.
Materials And Methods: Retrospective, non-interventional study, using the Clinical Practice Research Datalink Aurum primary care database, identified adults with type 2 diabetes (T2D) newly initiating a QW injectable GLP-1 RA between January 2020 and November 2021. Dual primary outcomes were proportion of patients with (1) HbA1c < 7% (<53 mmol/mol) and (2) weight loss categories (from 0% to 15+%) after 6 months of continuous GLP-1 RA therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!